<unk>  is an antineoplastic agent that is FDA approved for the treatment of multiple myeloma.   Common adverse reactions include fatigue, headache, nausea, diarrhea, constipation, decreased appetite, vomiting, lymphocytopenia, neutropenia, thrombocytopenia, anemia, back pain, arthralgia, leg pain, musculoskeletal chest pain, cough, nasal congestion, dyspnea, nasopharyngitis, pneumonia, and infusion-related reaction.
Daratumumab
Adecatumumab
Lexatumumab
Lanadelumab
Ofatumumab
Alirocumab
Raxibacumab
Ustekinumab